Evidence map›Paper›PMID 34513842›Full record

ArticleFrontiers in cell and developmental biology2021

Copy Number Signatures and Clinical Outcomes in Upper Tract Urothelial Carcinoma.

Bao Guan, Yuan Liang, Huan Lu, Zhengzheng Xu, Yue Shi, Juan Li, Wenwen Kong, Chuanyu Tian, Yezhen Tan, Yanqing Gong and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 2 countries.

Bao GuanDepartment of Urology, Peking University First Hospital, Beijing, China.
Yuan LiangKey Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
Huan LuKey Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
Zhengzheng XuKey Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
Yue ShiKey Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
Juan LiKey Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
Wenwen KongKey Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
Chuanyu TianKey Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
Yezhen TanKey Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
Yanqing GongDepartment of Urology, Peking University First Hospital, Beijing, China.
Jin LiuDepartment of Urology, The Third Hospital of Hebei Medical University, Shijiazhuang, China.
Dong FangDepartment of Urology, Peking University First Hospital, Beijing, China.
Qi ShenDepartment of Urology, Peking University First Hospital, Beijing, China.
Shiming HeDepartment of Urology, Peking University First Hospital, Beijing, China.
Muhammad ShakeelKey Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
Zhongyuan ZhangDepartment of Urology, Peking University First Hospital, Beijing, China.
Qun HeDepartment of Urology, Peking University First Hospital, Beijing, China.
Xuesong LiDepartment of Urology, Peking University First Hospital, Beijing, China.
Weimin CiKey Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
Liqun ZhouDepartment of Urology, Peking University First Hospital, Beijing, China.
Beijing Institute of Genomics · CNChinese Academy of Sciences · CNPeking University · CNPeking University First Hospital · CNUniversity of Chinese Academy of Sciences · CNThird Hospital of Hebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor staging of upper tract urothelial carcinomas (UTUCs) is relatively difficult to assert accurately before surgery. Here, we used copy number (CN) signatures as a tool to explore their clinical significance of molecular stratification in UTUC. CN signatures were extracted by non-negative matrix factorization from the whole-genome sequencing (WGS) data of 90 Chinese UTUC primary tumor samples. A validation UTUC cohort (

Indexed as

cell-free DNAcopy number signatureprognosisupper tract urothelial carcinomawhole-genome sequencing

Identifiers

PMID34513842
PMCPMC8427613
OpenAlexW3196796540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.